Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: Comparative proteomic analyses

Liu,Qing-Hua; Zhao,Chen-Yan; Zhang,Jing; Chen,Ying; Gao,Li; Ni,Can-Yong; Zhu,Ming-Hua

doi:10.3892/mmr.2012.1013

Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: Comparative proteomic analyses

Authors:
- Qing-Hua Liu
- Chen-Yan Zhao
- Jing Zhang
- Ying Chen
- Li Gao
- Can-Yong Ni
- Ming-Hua Zhu
View Affiliations

Affiliations: Department of Pathology, Changhai Hospital, Secondary Military Medical University, Shanghai, P.R. China
Published online on: July 31, 2012 https://doi.org/10.3892/mmr.2012.1013
Pages: 767-773

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The most notable obstacle hindering the effective treatment of human pancreatic cancer is intrinsic chemoresistance. In order to identify the candidate protein(s) responsible for the intrinsic chemoresistance, the protein expression profiling of human pancreatic adenocarcinoma cell line Capan-1 and its distinct surviving cells following primary treatment with gemcitabine (GEM) were compared by two-dimensional electrophoresis (2-DE) combined with liquid chromatography-mass spectrometry (LC-MS) or mass spectrometry (MS). In total, nine proteins were identified, and heat shock protein B1 (HSP27), one of the differentially expressed proteins, was selected for further validation. Furthermore, the results of western blotting and immunohistochemical staining indicated that HSP27 may be significant in pancreatic intrinsic chemoresistance to GEM. The findings of this study provide a platform for further elucidation of the underlying mechanisms of pancreatic cancer intrinsic chemoresistance and demonstrate that HSP27 may be a valid target for anticancer drug development.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar
3	Kawanami T, Takiguchi S, Ikeda N and Funakoshi A: A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin. Oncol Rep. 27:867–872. 2012.PubMed/NCBI
4	Kasuya K, Tsuchida A, Nagakawa Y, et al: Hypoxia-inducible factor-1alpha expression and gemcitabine chemotherapy. Oncol Rep. 26:1399–1406. 2011.PubMed/NCBI
5	Chen H, Wei W, Guo Y, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep. 25:1253–1261. 2011.PubMed/NCBI
6	Di Marco M, Di Cicilia R, Macchini M, et al: Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncol Rep. 23:1183–1192. 2010.PubMed/NCBI
7	Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
8	Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Jama. 304:1073–1081. 2010. View Article : Google Scholar
9	Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 1587:164–173. 2002. View Article : Google Scholar
10	Muerkoster S, Wegehenkel K, Arlt A, et al: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 64:1331–1337. 2004. View Article : Google Scholar
11	Yamauchi K, Yang M, Hayashi K, et al: Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 68:516–520. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG and Neuwelt EA: Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia. 11:187–195. 2009.PubMed/NCBI
13	Liu QH, Zhang J, Zhao CY, et al: Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. Cancer Lett. 314:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
14	Mosser DD and Morimoto RI: Molecular chaperones and the stress of oncogenesis. Oncogene. 23:2907–2918. 2004. View Article : Google Scholar : PubMed/NCBI
15	Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 5:2592–2601. 2006. View Article : Google Scholar : PubMed/NCBI
16	Zhao L, Liu L, Wang S, Zhang YF, Yu L and Ding YQ: Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol. 133:771–782. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kang SH, Kang KW, Kim KH, et al: Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer. 8:2862008. View Article : Google Scholar : PubMed/NCBI
18	Larkin SE, Holmes S, Cree IA, et al: Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer. 106:157–165. 2012. View Article : Google Scholar : PubMed/NCBI
19	Xia Y, Liu Y, Wan J, et al: Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem. 52:6083–6096. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ciocca DR and Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 10:86–103. 2005. View Article : Google Scholar : PubMed/NCBI
21	Soti C, Nagy E, Giricz Z, Vigh L, Csermely P and Ferdinandy P: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol. 146:769–780. 2005. View Article : Google Scholar : PubMed/NCBI
22	Schafer C, Seeliger H, Bader DC, et al: Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med. View Article : Google Scholar : 2011.PubMed/NCBI
23	Berrieman HK, Cawkwell L, O'Kane SL, Smith L and Lind MJ: Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer. Oncol Rep. 15:283–286. 2006.PubMed/NCBI
24	Yang YX, Xiao ZQ, Chen ZC, et al: Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics. 6:2009–2021. 2006. View Article : Google Scholar : PubMed/NCBI
25	Liao WC, Wu MS, Wang HP, Tien YW and Lin JT: Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas. 38:422–426. 2009. View Article : Google Scholar : PubMed/NCBI
26	Leonardi R, Pannone G, Magro G, Kudo Y, Takata T and Lo Muzio L: Differential expression of heat shock protein 27 in normal oral mucosa, oral epithelial dysplasia and squamous cell carcinoma. Oncol Rep. 9:261–266. 2002.PubMed/NCBI
27	Vargas-Roig LM, Gago FE, Tello O, Aznar JC and Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer. 79:468–475. 1998. View Article : Google Scholar : PubMed/NCBI
28	Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al: Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 31:1345–1350. 2007.PubMed/NCBI
29	Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al: A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Report. 1:429–434. 2008.PubMed/NCBI
30	Heinrich JC, Tuukkanen A, Schroeder M, Fahrig T and Fahrig R: RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol. 137:1349–1361. 2011. View Article : Google Scholar : PubMed/NCBI
31	Arrigo AP: Hsp27: novel regulator of intracellular redox state. IUBMB Life. 52:303–307. 2001. View Article : Google Scholar : PubMed/NCBI
32	Nakashima M, Adachi S, Yasuda I, et al: Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Lett. 313:218–225. 2011. View Article : Google Scholar : PubMed/NCBI
33	Taba K, Kuramitsu Y, Ryozawa S, et al: Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res. 30:2539–2543. 2010.PubMed/NCBI
34	Baylot V, Andrieu C, Katsogiannou M, et al: OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2:e2212011. View Article : Google Scholar : PubMed/NCBI